Marinus Pharmaceuticals Inc has a consensus price target of $20.9, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Oppenheimer, and RBC Capital on March 26, 2024, March 7, 2024, and March 6, 2024. With an average price target of $20 between HC Wainwright & Co., Oppenheimer, and RBC Capital, there's an implied 121.24% upside for Marinus Pharmaceuticals Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
03/26/2024 | MRNS | Buy Now | Marinus Pharma | $9.04 | 198.67% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
03/07/2024 | MRNS | Buy Now | Marinus Pharma | $9.04 | -0.44% | Oppenheimer | Jay Olson | $9 → $9 | Maintains | Perform | Get Alert |
03/06/2024 | MRNS | Buy Now | Marinus Pharma | $9.04 | 165.49% | RBC Capital | Brian Abrahams | → $24 | Reiterates | Outperform → Outperform | Get Alert |
03/06/2024 | MRNS | Buy Now | Marinus Pharma | $9.04 | 198.67% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
12/05/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 198.67% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
11/08/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 176.55% | Truist Securities | Joon Lee | $32 → $25 | Maintains | Buy | Get Alert |
09/21/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 209.73% | Cantor Fitzgerald | Charles Duncan | → $28 | Reiterates | Overweight → Overweight | Get Alert |
09/20/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 132.3% | RBC Capital | Brian Abrahams | $20 → $21 | Maintains | Outperform | Get Alert |
09/20/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 198.67% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 198.67% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
08/11/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 121.24% | RBC Capital | Brian Abrahams | $21 → $20 | Maintains | Outperform | Get Alert |
08/11/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 253.98% | Truist Securities | Joon Lee | $42 → $32 | Maintains | Buy | Get Alert |
08/11/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 43.81% | Ladenburg Thalmann | Michael Higgins | $17 → $13 | Maintains | Buy | Get Alert |
08/11/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 121.24% | Baird | Brian Skorney | $24 → $20 | Maintains | Outperform | Get Alert |
08/11/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 54.87% | Oppenheimer | Jay Olson | → $14 | Downgrade | Outperform → Perform | Get Alert |
06/23/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 209.73% | Cantor Fitzgerald | Charles Duncan | $28 → $28 | Reiterates | Overweight → Overweight | Get Alert |
06/14/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 198.67% | HC Wainwright & Co. | Douglas Tsao | → $27 | Reiterates | Buy → Buy | Get Alert |
05/30/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 99.12% | JMP Securities | Jason West | → $18 | Reiterates | Market Outperform → Market Outperform | Get Alert |
05/12/2023 | MRNS | Buy Now | Marinus Pharma | $9.04 | 364.6% | Truist Securities | Joon Lee | $50 → $42 | Maintains | Buy | Get Alert |
The latest price target for Marinus Pharma (NASDAQ: MRNS) was reported by HC Wainwright & Co. on March 26, 2024. The analyst firm set a price target for $27.00 expecting MRNS to rise to within 12 months (a possible 198.67% upside). 22 analyst firms have reported ratings in the last year.
The latest analyst rating for Marinus Pharma (NASDAQ: MRNS) was provided by HC Wainwright & Co., and Marinus Pharma reiterated their buy rating.
There is no last upgrade for Marinus Pharma.
The last downgrade for Marinus Pharmaceuticals Inc happened on August 11, 2023 when Oppenheimer changed their price target from N/A to $14 for Marinus Pharmaceuticals Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Marinus Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Marinus Pharma was filed on March 26, 2024 so you should expect the next rating to be made available sometime around March 26, 2025.
While ratings are subjective and will change, the latest Marinus Pharma (MRNS) rating was a reiterated with a price target of $0.00 to $27.00. The current price Marinus Pharma (MRNS) is trading at is $9.04, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.